Clinical Trial

Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease

Study acronym: SSc-mILD
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this pilot study is to assess the feasibility of a larger study on the efficacy of mycophenolate mofetil in people diagnosed with systemic sclerosis with mild lung involvement. Participants will be recruited over 12 months at 3 academic centers and assigned randomly to receive either mycophenolate mofetil or placebo, a look-alike substance that contains no active drug, for 96 weeks.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-03-14; most recent amendment 2025-04-09.
Status change: Not Yet Recruiting → Recruiting 2025-04-09
Trial Details
NCT Number NCT05785065
Lead Sponsor Centre hospitalier de l'Université de Montréal (CHUM)
Collaborators: McGill University, University of Calgary, Jewish General Hospital, Canadian Institutes of Health Research (CIHR), Sclérodermie Québec, Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Conditions Systemic Sclerosis With Lung Involvement, Systemic Sclerosis, Interstitial Lung Disease
Enrollment 35 participants
Start Date 2024-08-29
Primary Completion 2026-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-04-11